The 2018 Annual General Meeting of Orion was held on Tuesday, 20 March 2018 in Helsinki.
18 July 2018 I Half-Year Financial Report 1-6/2018 and related materials are published. View CEO's webcast presentation or have a look at Orion's latest investor slide set.
The Closing of the transaction took place on 30 April 2018.
26 Feb 2018 I Orion's Financial Statement documents for 2017 are published, and include Financial Statements, the report of the Board of Directors and the Auditor's report.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
From the sustainability section you will find, among others, our Sustainability reports, Code of Conduct and Quality Policy.
